Phase 2 Pancreatic Cancer Trial, Recruiting NCT06758544 Sponsor: Guangdong Provincial People's Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT06758544
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part and have signed an approved consent form before any study-related procedures begin.
  • People aged 18 to 75 years old at the time of the screening visit.
  • People who have been clinically diagnosed with pancreatic cancer.
  • People with a good to fully active physical functioning level, meaning they are either fully active or have only minor restrictions on physically demanding activity (this is measured by a standard scale called the ECOG score of 0 or 1).
  • People with an expected survival time of at least 6 months.
  • People without serious problems affecting their blood, heart, liver, kidneys, or blood clotting.

Who may not be able to join:

  • People who have previously received a type of cancer therapy called an oncolytic virus treatment, or any other systemic (whole-body) treatment for pancreatic cancer.
  • People who have previously had a stem cell transplant from a donor or an organ transplant.
  • People whose immune systems are weakened or not functioning properly.
  • People with a known dependency on alcohol or drugs.
  • People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 020-83525210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Guangdong Provincial People's Hospital
Registry
ClinicalTrials.gov
Start date
17 March 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety and tolerability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov